A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: D. R. Camidge, S. G. Eckhardt, S. Diab, L. Gore, L. Chow, C. O’Bryant, E. Temmer, A. Ervin-Haynes, T. Katz, F. Fox, R. B. Cohen
Institutions: Fox Chase Cancer Center, University of Colorado Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2267395365